Children's Hospital, University of Duisburg-Essen, Department of Paediatrics II, Hufelandstr. 55, 45122 Essen, Germany.
Nephrol Dial Transplant. 2010 Apr;25(4):1257-65. doi: 10.1093/ndt/gfp595. Epub 2009 Nov 23.
Newborns with inborn errors of metabolism often present with hyperammonaemic coma, requiring prompt diagnosis and specific medical therapy, nutritional support and efficient toxin removal. Little information regarding the efficacy and safety of continuous venovenous haemodialysis (CVVHD) as an option for extracorporal ammonia detoxification in children is available.
Twenty-one patients with hyperammonaemia [19 neonates (mean age 4.1 +/- 2.4 days) and two children 1 and 7 years of age, respectively] were admitted to our hospital for dialysis between 1996 and 2008. Seventeen children (15 neonates), received CVVHD. Four neonates received continuous peritoneal dialysis (CPD). All started medical treatment with sodium benzoate, l-arginine hydrochloride and carnitine as well as protein-restricted parenteral diets with high caloric intake before dialysis.
Plasma ammonia levels (range 464-7267 microg/dl before dialysis and 27-3317 microg/dl after dialysis) were significantly reduced by 50% within 4.7 +/- 2.5 h with CVVHD compared with 13.5 +/- 6.2 h with CPD (P < 0.0001). Plasma ammonia levels <200 microg/dl critical range were achieved within 22.4 +/- 18.1 h in CVVHD patients compared with 35.0 +/- 24.1 h with CPD. Depending on the weight and blood pressure stability of the patients, mean blood flow velocities of 9.8 +/- 3.4 ml/kg/min and mean dialysate flow rates of 3925 +/- 2398 ml/min/1.73 m(2) were employed. Blood and dialysate flows significantly correlated with ammonia clearance and decay of ammonia in vivo. Because of the severe underlying disease, 18% of CVVHD patients died compared with 50% undergoing CPD. In total, 82% of CVVHD patients survived the first 6 months after dialysis. Among these, 43% were without sequelae, 43% developed moderate mental retardation, and two (14%) developed severe mental retardation.
CVVHD effectively and quickly eliminates plasma ammonia. To optimize long-term mental outcome, rapid identification and appropriate treatment of the underlying disease as well as starting dialysis early are of enormous therapeutic value.
患有先天性代谢错误的新生儿常出现高氨血症性昏迷,需要及时诊断和进行特定的医学治疗、营养支持和有效的毒素清除。有关连续静脉-静脉血液透析(CVVHD)作为儿童体外氨解毒的一种选择的疗效和安全性的信息很少。
1996 年至 2008 年间,21 名高氨血症患儿(19 名新生儿(平均年龄 4.1±2.4 天)和 2 名 1 岁和 7 岁的儿童)被收入我院接受透析治疗。17 名儿童(15 名新生儿)接受 CVVHD。4 名新生儿接受连续腹膜透析(CPD)。所有患儿在透析前均接受苯甲酸钠、盐酸精氨酸和肉碱治疗,并接受高蛋白限制的肠外高热能饮食。
与 CPD 组(13.5±6.2h)相比,CVVHD 组患儿在 4.7±2.5h 内血浆氨水平(透析前为 464-7267μg/dl,透析后为 27-3317μg/dl)降低 50%(P<0.0001)。CVVHD 组患儿的血浆氨水平<200μg/dl 临界值的时间为 22.4±18.1h,而 CPD 组为 35.0±24.1h。根据患儿的体重和血压稳定性,平均血流速度为 9.8±3.4ml/kg/min,平均透析液流速为 3925±2398ml/min/1.73m2。血液和透析液流量与氨清除率和体内氨衰减显著相关。由于基础疾病严重,CVVHD 组患儿的死亡率为 18%,而 CPD 组患儿的死亡率为 50%。在接受 CVVHD 治疗的患儿中,共有 82%在透析后 6 个月内存活,其中 43%无后遗症,43%出现中度精神发育迟滞,2 名(14%)出现重度精神发育迟滞。
CVVHD 可有效快速地清除血浆氨。为了优化长期精神预后,早期识别和适当治疗基础疾病以及早期开始透析具有巨大的治疗价值。